EA202090881A1 - Комбинированные способы терапии для лечения злокачественной опухоли - Google Patents

Комбинированные способы терапии для лечения злокачественной опухоли

Info

Publication number
EA202090881A1
EA202090881A1 EA202090881A EA202090881A EA202090881A1 EA 202090881 A1 EA202090881 A1 EA 202090881A1 EA 202090881 A EA202090881 A EA 202090881A EA 202090881 A EA202090881 A EA 202090881A EA 202090881 A1 EA202090881 A1 EA 202090881A1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
malignant tumor
combined therapy
therapy methods
signaling
Prior art date
Application number
EA202090881A
Other languages
English (en)
Inventor
Кит В. Микьюл
Каймин Сунь
Цзин Юй Ван
Цзэбинь Ван
Original Assignee
Тесаро, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Тесаро, Инк. filed Critical Тесаро, Инк.
Priority claimed from PCT/US2018/053542 external-priority patent/WO2019067978A1/en
Publication of EA202090881A1 publication Critical patent/EA202090881A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Настоящее изобретение относится к способам лечения злокачественной опухоли посредством комбинированной терапии средством, которое ингибирует передачу сигнала белком запрограммированной смерти 1 (PD-1), и средством, которое ингибирует передачу сигнала поли[ADP-рибоза]полимеразой (PARP).
EA202090881A 2018-04-06 2018-09-28 Комбинированные способы терапии для лечения злокачественной опухоли EA202090881A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862654024P 2018-04-06 2018-04-06
PCT/US2018/053542 WO2019067978A1 (en) 2017-09-30 2018-09-28 POLYTHERAPIES FOR THE TREATMENT OF CANCER

Publications (1)

Publication Number Publication Date
EA202090881A1 true EA202090881A1 (ru) 2020-08-05

Family

ID=72235059

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202090881A EA202090881A1 (ru) 2018-04-06 2018-09-28 Комбинированные способы терапии для лечения злокачественной опухоли

Country Status (1)

Country Link
EA (1) EA202090881A1 (ru)

Similar Documents

Publication Publication Date Title
MX2019013755A (es) Terapias de combinación para el tratamiento del cáncer.
EA201792191A1 (ru) Комбинированная терапия fgfr/pd-1 для лечения злокачественной опухоли
EA202090776A1 (ru) Визуализирующие и радиотерапевтические агенты, нацеленные на фибробласт-активирующий белок-альфа (fapalpha)
EA201990912A1 (ru) Анти-lag-3 антитела и их композиции
MD3455259T2 (ro) Combinație de anticorpi anti-PD-1 și radiație pentru tratarea cancerului
EA201890730A1 (ru) Производные пиразолопиримидина в качестве ингибиторов btk для лечения злокачественного новообразования
MX2023001527A (es) Compuestos con actividad inductora de ferroptosis y metodos de uso de estos.
MX2019013373A (es) Terapias de combinación para tratar cáncer.
MX2018008426A (es) Combinaciones anti-egfr para tratar tumores.
EA201890146A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ СОЛИДНЫХ ОПУХОЛЕЙ С ИСПОЛЬЗОВАНИЕМ КОМБИНИРОВАННОЙ ТЕРАПИИ ИНГИБИТОРОМ mTOR В ВИДЕ НАНОЧАСТИЦ
CR20220626A (es) Compuestos para el tratamiento de enfermedades y trastornos asociados a braf
EA201991622A1 (ru) Комплексная терапия для лечения рака
EA202192122A1 (ru) Соединения, обладающие активностью индуцирования ферроптоза, и способы их применения
MX2020008680A (es) Terapia de combinacion con apilimod y agentes glutamatergicos.
BR112018075660A2 (pt) métodos de tratamento de câncer de pâncreas
MX2019006331A (es) Métodos para tratar el cáncer usando anticuerpos anti-pd-l1 y antiandrógenos.
EA202091539A1 (ru) Комбинированная терапия против злокачественной опухоли антагонистом iap и молекулой против pd-1
EA201990567A1 (ru) Комбинированная терапия с ингибиторами глутаминазы
MX2019008233A (es) Nanoconjugados de doxorrubicina y oro dirigidos para terapia tumoral.
EA201891968A1 (ru) Комбинированное лечение с использованием liv1-adc и химиотерапевтического средства
EA202092540A1 (ru) Комбинации для лечения рака
MX2024000082A (es) Ligandos de crbn con (r)-glutarimida y métodos de uso.
EA202192757A1 (ru) Способ лечения опухолей
EA201892631A1 (ru) Дигидротестостерон и производные и промоторы дигидротестостерона в лечении рака
EA201992594A1 (ru) Комбинированные терапии для лечения рака